Watch for 52-week data from EVERLAST-A in December 2026, which will be the key durability readout for ORKA-001 ahead of Phase 3 initiation. Also monitor ORKA-002 Week 16 data in Q1 2027 for pipeline breadth validation.
Drugs in focus
ORKA drug pipeline →ORKA-001
▲ Bullish Named in this press release- Impact
- Phase
- Phase 2b
- Time to market
- If Phase 3 trials begin in 1H 2027 and run successfully, a BLA submission and potential FDA approval would likely be several years away, possibly in the 2029-2030 timeframe. The company has stated its $1.1 billion cash position funds operations through a BLA filing.
- Next catalyst
- None dated
What to watchThe key catalyst to watch is the EVERLAST-A 52-week data expected in December 2026, which will demonstrate whether ORKA-001's skin-clearing responses hold up a full year after just two doses. Strong durability would reinforce the ultra-durable dosing thesis and support the Phase 3 design. Weak durability would challenge the core value proposition. Phase 3 initiation in 1H 2027 and ORKA-002 Phase 2 data in Q1 2027 are secondary catalysts. The $1.1B cash runway removes financing overhang through a BLA filing.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $109.50entry
- T+1 · 6d ago −2.13%α −3.45% · $107.17
- T+4 · todayOpen
- T+5 · in 7h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oruka reported a Q3 2026 net loss of $50.0M ($0.63 per share) vs consensus of -$0.62, with no revenue. The key positive was strong Phase 2b data for ORKA-001 showing 61% PASI 100 at Week 16, consistent with prior results, and plans to start Phase 3 in 1H 2027. Cash position remains strong at $1.2B.
Key Financial Metrics
Key Facts
- Q3 2026 net loss $50.0M ($0.63 per share) vs consensus -$0.62
- Cash, cash equivalents and marketable securities of $1.2B as of Sep 30, 2026
- ORKA-001 Phase 2b EVERLAST-B: 61% PASI 100, 86% PASI 90 at Week 16 (high-dose 600mg)
- EVERLAST-A Week 28 data showed deepening responses: 71% PASI 100, 87% PASI 90
- Phase 3 program for ORKA-001 on track to begin 1H 2027
- ORKA-002 ORCA-SURGE Phase 2 enrollment completed (171 patients), Week 16 data expected Q1 2027
- R&D expenses $53.7M vs $29.0M YoY; G&A $8.4M vs $5.1M YoY
- Net cash used in operating activities $44.3M for Q3 2026
Financial Impact
Net loss of $50.0M in Q3 2026, cash burn $44.3M; cash position $1.2B provides runway through multiple catalysts
Risk Factors
- Clinical-stage biotech with no approved products or revenue; net loss widening YoY
- Phase 3 program not yet initiated; regulatory discussions pending
- Cash burn rate increasing ($44.3M operating cash outflow in Q3 vs $21.6M in Q3 2025)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3398930 |
Track record
40 reports on ORKA
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Viewing Entry $109.50 Now $99.24 −9.37% settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers